Clinical Efficacy of Corticosteroids in the Early Stages of Deterioration in COVID-19 Pneumonia.
Infect Drug Resist
; 14: 2667-2674, 2021.
Article
in English
| MEDLINE | ID: covidwho-1319550
ABSTRACT
BACKGROUND:
The World Health Organization (WHO) strongly suggests using corticosteroids in patients with severe coronavirus disease 2019 (COVID-19). Similarly, a large randomized controlled clinical trial (RCT) in the UK found that dexamethasone effectively reduced the mortality rate in severe COVID-19 patients. However, the safety profile of corticosteroids has been a controversial area of study. CASE DESCRIPTION A case of a COVID-19 patient is described and the clinical characteristics are observed as the mildly symptomatic patient progresses into a critically ill patient and during their dramatic improvement with corticosteroid therapy in the early stage of the deterioration process with COVID-19 pneumonia.CONCLUSION:
The most suitable timing and dosage for the use of corticosteroids to maximize its effect during the worsening of COVID-19 pneumonia are discussed. One of the main pathophysiological hypotheses for severe COVID-19 patients is related to cytokine storm and virus load, which can be effectively treated with corticosteroid therapy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Infect Drug Resist
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS